Summary

A 3-drug (3D) regimen of ABT-450, co-dosed with ritonavir, ombitasvir and dasabuvir has been given alone or in combination with ribavirin (RBV) and studied in 6 phase 3 trials of more than 2700 patients. The 3D regimen is safe and effective in patients infected with hepatitis C virus (HCV) genotype 1a with or without cirrhosis. However, efficacy of this treatment may be variably influenced by HCV genotype subtype, treatment experience (naïve vs experienced), and stage of fibrosis (early fibrosis vs cirrhosis). This article discusses an analysis of the SAPPHIRE-I and -II, PEARL-IV, and TURQUOISE-II trials to examine the impact of RBV in noncirrhotic patients and treatment duration in cirrhotic patients.